From The Editor
-
Industry Leaders On Analytical Method Development
1/7/2025
Experts from Bristol Myers Squibb and Moffitt Cancer Center discuss best practices for analytical method development, as well as how to manage the successful transfer of these methods.
-
Optimism For Biopharma In 2025
12/27/2024
In this closing segment from the executive roundtable discussion, our panelists express their confidence in the industry's mission and maintain a positive outlook for the years ahead.
-
How Biotechs Can Navigate Market Uncertainty In 2025
12/27/2024
In this segment of the executive roundtable discussion, our panelists weigh in on how to prepare for what may be a challenging financial climate in 2025.
-
Political Influences And Regulatory Implications For Biotech In 2025
12/27/2024
In this segment of the executive roundtable discussion, our panelists discuss the changing political landscape and its potential effects from a regulatory and economic point of view.
-
2025 Predictions For AI Use In Biotech
12/26/2024
In this segment of the executive roundtable discussion, our panelists discuss the growing prevalence of AI and its implications, both good and bad. They share their thoughts on smart adoption and the need for regulatory guidance moving forward.
-
Cell Therapy Manufacturing Trends And Advancements Continuing In 2025
12/26/2024
In this segment of the executive roundtable discussion, our panelists reflect on recent advances in cell therapy manufacturing and discuss active areas of innovation.
-
Exciting Areas Of Innovation For Cell Therapies
12/23/2024
In this segment of the executive roundtable discussion, our panelists express optimism about the promising future of allogeneic cell therapies and discuss other innovations in the field.
-
ADCs: Leading With The Linker
12/20/2024
Leo Marx, Ph.D., the Medicinal Chemistry Project and Bioconjugation Manager at Debiopharm, shares his company's rationale for the company's ADC development decisions and why its linker technology is the tip of the spear for those that make the cut.
-
Antibodies 2025: Venerable & Naked Or Complex & Multi-Specific?
12/19/2024
Antibodies are the biotherapeutic bulwark, the steadfast stalwart in not just oncology, but infectious and chronic inflammatory diseases as well. We consulted with a variety of antibody developers for insight into the challenges and opportunities antibody modalities face in the coming year and beyond.
-
Leveraging Directed Evolution To Optimize AAV Vector Design
12/18/2024
4D Molecular Therapeutics (4DMT) CEO and co-founder, David Kirn, MD, talks about the company’s approach to vector optimization, its product development, and its stage-appropriate buildup of internal GMP manufacturing.